醫療醫藥股受捧 春立/復銳/愛康/華領漲14%-17%
全球新冠疫潮未受控，近期多國更出現疫情反彈，且單日新增確診宗數創紀錄高，尤其是疫情肆虐的印度繼昨天新增確診病例超過31.4萬宗新高後，今天新增確診進一步急增逾33萬宗，連續第二天打破美國所創單日確診逾29.7萬宗紀錄，成為全球疫情爆發以來單日感染宗數最高國家，導致醫療系統瀕臨崩潰，日本多區周日起也會進入第三次緊急狀態。另外，內地多隻醫療醫藥股季績理想，加上內地近期醫美概念股受捧股價連日急漲，激發市場對醫療醫藥股熱情。
本港相關股中，由復星醫藥(02196.HK)分拆上市的以色列醫學美容器械製造商復銳醫療科技(01696.HK)升幅顯著，該公司全資附屬擬斥3.1億人民幣全購復星牙科，股價三連漲，午後高見9.62元，再創2017年9月上市以來新高，現造9.3元，急漲15%，成交續增至767萬股。復星醫藥三連漲，今天股價高見39.95元，現造39.37元，續升逾3%。
獲高盛升級至「買入」看14.91元的愛康醫療(01789.HK)升幅最大，股價重越百天線(12.3元)，最高見12.76元，現造12.5元，急漲17%，成交增至2,532萬股。獲高盛仍看14.4元的康基醫療(09997.HK)高見12.48元，現造12.16元，續升9%。
春立醫療(01858.HK)高見24.9元，創逾三個月高，現造24.55元，急漲14%，成交增至293萬股。
華領醫藥-B(02552.HK)由低位連升第二天，今天股價重越10天、20天及50天線(4.23-4.7元)，最高見5.02元，現造4.95元，續漲17%，一向疏落的成交增至359萬股。康寧傑瑞製藥-B(09966.HK)三連漲，今天股價升破50天線(12.35元)，最高見13.02元，現造12.88元，續升6%。信達生物(01801.HK)六連升，今天股價高見90.25元，現造89.6元，續升3.8%。
藍籌藥明生物(02269.HK)高見115.4元，現造114.5元，續升3.9%；藥明康德(02359.HK)反覆續升4.5%，報172元。亞盛醫藥-B(06855.HK)續升3%曾高見39.8元，創兩個月高。
石藥(01093.HK)續升3.3%報9.92元。威高股份(01066.HK)三連升，今天股價重越牛熊線(15.77元)，最高見16.72元，現造16.58元，續升6.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
